The Superviga (Sildenafil citrate) is a peroral preparation for path genetic therapy of erection dysfunction.
Contra-indications: Application Supervi gacontraindicated to the patient, NO accepting donors or nitrates in any medicinal form. In case of simultaneous application with nitrates Sildenafil strengthens their vasodilation effect that leads to the considerable falling of arterial pressure. Application method: The recommended initial dose of a preparation of 50 mg is accepted as required approximately in 60 minutes prior to sexual activity. Proceeding from efficiency and portability of a preparation the dose can be increased to 100 mg or to lower to 25 mg. Maximum dose of 100 mg. Recommended frequency of reception of 1 times per day.
Erection gain — effect of achievement of a resistant erection by increase of level of TsGMF that leads to lowering of intracellular concentration of calcium and a relaxation of cells of a body with the subsequent filling of sine with blood against increase in an arterial blood-groove in a penis and a carrying-out veins. Additional pharmacological effects: hypotensive effect (at the expense of modulating influence on NO that leads to a vazodilatat of arterial and venous peripheral tanks) — lowering of systolic pressure upon 8,4 mm of mercury., the diastolic — on 5,5 mm of mercury. The Supervi gadoesn't influence reproductive function, doesn't change composition and properties of sperm, and doesn’t show mutagen and cancer genic properties, the preparation doesn't influence a sexual tendency. Sildenafil is quickly inhausted.
Concentration of a preparation in plasma after reception it inside on an empty stomach reaches a pica within 30-120 minutes, on the average — 60 minutes (we will mark essential importance of this concept for a customer of Superviga). Absolute bioavailability in case of intake on the average makes 41 % (25-63 %). The semi-deduction period is 3-5 hours. After intake it is deduced in the form of metabolites generally through (about 80 %) and to a lesser extent through kidneys (about 13 %).The Supervigais the TsGMF selective inhibitor — specific the fifth type (FDE5) which is responsible for TsGMF decay in fabrics of a cavernous body of a penis.
The Superviga doesn't render direct weakening action on smooth muscles of cavernous bodies of a penis, but strengthens NO action on them.Application Superviga contraindicated to the patient, NO accepting donors or nitrates in any medicinal form. In case of simultaneous application with nitrates Sildenafil strengthens their vasodilation effect that leads to the considerable falling of arterial pressure.